Procter & Gamble Health Ltd. Share Price

P&G Health Q2 Sales Rise 18%, PAT Jumps 26%

PGHL (PGHL) reported double-digit growth in its second-quarter FY27 results, with sales increasing 18% year-on-year to ₹376 crore for the quarter ended September 30, 2026. Profit after tax (PAT) rose 26% to ₹112 crore, supported by sales growth and productivity improvements across the value chain. According to the company, the performance was driven by strong brand fundamentals, effective retail execution, positive consumer response to new product innovations and strengthened go-to-market capabilities. Managing Director Milind Thatte highlighted the growing consumer focus on preventive healthcare and the positive response from consumers, patients and healthcare professionals to the company's science-backed healthcare products. The company also credited its consumer communication initiatives, healthcare professional awareness programmes and improved supply chain capabilities for supporting business growth. PGHL operates in India's vitamins, minerals and supplements (VMS) segment, with established brands including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Its strategy focuses on a portfolio of trusted healthcare brands, product superiority, innovation, retail execution and productivity. The latest results indicate continued growth in both revenue and profitability. Investors will monitor whether the company can sustain this momentum through new product launches, stronger distribution and continued demand for preventive healthcare products. Disclosure: I do not hold any position or financial interest in the mentioned stock.

P&G Hygiene: Premium Brands & Strong Dividends

PGHL Procter & Gamble Hygiene & Health Care (PGHH) has a strong portfolio in feminine hygiene, healthcare and personal care, led by brands such as Whisper and Vicks. FY26 net profit rose 34.5%, while Q4 revenue declined 5.1% YoY and net profit fell about 2% to ₹153 crore, reflecting near-term demand and cost pressures. Latest News: The company continues to focus on premiumisation, innovation and strengthening its core brands. P&G globally expects FY27 sales growth of 1–3%, with higher input and marketing costs remaining a concern. Corporate Action: PGHH declared a ₹60/share final dividend for FY26. Earlier, it paid an interim ₹195/share, including a ₹25 special dividend. Strong brands, pricing power and exceptional dividend payouts support the long-term case, while premium valuation, weak volume growth and input-cost inflation remain key risks.

Stocks having high delivery quantity as on 22.08.2025

1. Karur Vysya Bank 2. PGHL 3. Netweb Technologies India 4. PTC Industries 5. JB Chemicals 6. ABFRL 7. Zen Technologies KARURVYSYA

Companies having ex dividend on 22.08.205

1. ABM Knowledgeware Rs. 1.25 per share 2. AK Capital Services Rs. 14 per share 3. APL Apollo Tubes Rs. 5.75 per share 4. ASM Technologies Rs. 1 per share 5. Bannari Amman Sugars Rs. 12.5 per share 6. Deep Industries Rs. 3.05 per share 7. DAPS Advertising Rs. 0.2 per share 8. eClerx Services Rs. 1 per share 9. Gujarat Ambuja Exports Rs. 0.25 per share 10. IRCTC Rs. 1 per share 11. Jindal Stainless Rs. 2 per share 12. Jindal Steel Rs. 2 per share 13. KFin Technologies Rs. 7.5 pe share 14. LIC Housing Finance Rs. 10 per share 15. Lodha Developers Rs. 4.25 pe share 16. Netweb Technologies Rs. 2.5 per share 17. Procter & Gamble Health Rs. 45 per share 18. The Federal Bank Rs. 1.2 per share IRCTC

close crossing 52 week high

PGHL - New 52-Week High: Reached a new milestone in its upward journey. - Price Appreciation: Notable increase in stock price. - Strong Bullish Trend: Robust upward momentum driven by positive market sentiment. - Increased Investor Confidence: Investors are becoming more confident in the company's prospects. - Positive Market Sentiment: Overall positive sentiment contributing to upward momentum. Disclaimer: Investing and Trading in Stock Market is risky activity. Always trade with a stop loss. Do not Trade's invest by taking loan and trade only with the money that you can afford to risk. Do not put your entire capital in one single Trade.

P&G Health Q4 updates

PGHL numbers from Q4 announcement - Revenue at ₹311 crore versus ₹252.2 crore, up 23.2% Net profit at ₹61.18 crore versus ₹46.56 crore, up 31.3% EBITDA at ₹81 crore versus ₹67.5 crore, up 20.2% Margin at 26.08% versus 26.73%